Scimago Lab
powered by Scopus
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST


eISSN: 2329-0358

Home Page

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more

Published: 2019-11-12

Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients

Lin Yan, Zhi-Qiang Yang, Yun-Ying Shi, Jing Ren, Cui-Li Yang, Zheng-Li Wan, Yang-Juan Bai, Li-Mei Luo, Lan-Lan Wang, Yi Li

(Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland))

Ann Transplant 2019; 24:594-604

DOI: 10.12659/AOT.918980

BACKGROUND: Tacrolimus is a widely used immunosuppressant in renal transplant recipients. It was demonstrated in rats and healthy volunteers that Wuzhi capsules could inhibit metabolism and maintain blood concentration of tacrolimus. However, there are no clinical studies of Wuzhi capsules in renal transplant recipients. This research aimed to assess the effect of Wuzhi capsules on the blood concentration of tacrolimus in renal transplant recipients.
MATERIAL AND METHODS: A total of 158 Chinese renal transplant recipients receiving tacrolimus with or without Wuzhi capsules were included in this retrospective study. The cohort study included 126 recipients, with 86 recipients receiving Wuzhi capsules (WZCs) and the other 40 recipients not receiving WZCs. Another 32 recipients were involved in a self-control study.
RESULTS: Dose- and body weight-adjusted trough concentrations (C0/D/W) of tacrolimus in the WZC group were found to be significantly higher than that in the non-WZC group (P<0.05). The improvement of C0/D/W by administration of Wuzhi capsules was more significant in CYP3A5 expressers than in non-expressers following subgroup analysis. Furthermore, the WZC group had a remarkably higher proportion of subjects who reached target tacrolimus concentration than in the non-WZC group, both in CYP3A5 expressers (P=0.01) and non-expressers (P<0.001). Multiple linear regression analysis and self-control analysis confirmed the positive impact of Wuzhi capsules on tacrolimus concentration (P<0.001).
CONCLUSIONS: Wuzhi capsules can increase tacrolimus trough concentration without adverse effects on allograft function, especially in CYP3A5 expressers. Efficient and convenient immunosuppressive effects on renal transplant recipients can be achieved by treatment including administration of Wuzhi capsules.

Keywords: Cytochrome P-450 CYP3A, Drugs, Chinese Herbal, Kidney Transplantation, Tacrolimus

Related Articles (0)

Coming Soon...

Published: 2019-11-01

Overcoming Hepatic Artery Thrombosis After Living Donor Liver Transplantations: An Experience from Asan M...

Gil-Chun Park, Deok-Bog Moon, Sang-Hyun Kang, Chul-Soo Ahn, Shin Hwang, Ki-Hun Kim, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Yong-In Yoon, Sung-Gyu Lee

Ann Transplant 2019; 24:588-593

DOI: 10.12659/AOT.919650

Published: 2019-10-22

BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous...

Ana Lucia Ron-Magaña, Omar Eduardo Fernandez-Vargas, Esperanza Barrera-Chairez, Carlos Silvestre Ron-Guerrero, Ana Jaqueline Bañuelos-Ávila

Ann Transplant 2019; 24:584-587

DOI: 10.12659/AOT.918259